针对骨髓移植病患中铁过载的去铁治疗研究进展

doi:10.16288/j.yczz.15-195

[an error occurred while processing this directive]

HEREDITAS(Beijing) ›› 2015, Vol. 37 ›› Issue (9): 865-872.doi: 10.16288/j.yczz.15-195

• Reviews • Previous Articles Next Articles

Progress of iron-chelating therapy for iron overload in patients after bone marrow transplantation

Shiwei Li¹, Xiang Li², Feng Guan¹

1. School of Biotechnology, Jiangnan University, Wuxi 214122, China;
2.Wuxi Medical School, Jiangnan University, Wuxi 214122, China

Received:2015-05-06 Revised:2015-07-22 Online:2015-09-20 Published:2015-09-20

Abstract

Abstract: Bone marrow transplantation (BMT) is commonly used to treat hematopoietic system malignant diseases. Iron overload, which is one of the most common complications in patients undergoing BMT, has a negative impact on survival after allogeneic transplantation. Better understanding of molecular mechanisms of iron overload can improve the treatment regime and improve the efficiency for iron-chelating therapy. In this review, we summarize the mechanisms of iron overload in various conditions and the progression of iron-chelating strategies in patients undergoing BMT. This review will provide insights into the prevention and treatment of patients with iron overload after BMT.

Key words: bone marrow transplantation, iron overload, iron-chelating therapy

Shiwei Li, Xiang Li, Feng Guan. Progress of iron-chelating therapy for iron overload in patients after bone marrow transplantation[J]. HEREDITAS(Beijing), 2015, 37(9): 865-872.

References

[1] Bystrom LM, Guzman ML, Rivella S. Iron and reactive oxygen species: friends or foes of cancer cells?. Antioxid Redox Sign , 2014, 20(12): 1917-1924.
[2] Estevão IF, Junior PP, Bonini-Domingos CR. Serum ferritin and transferrin saturation levels in β 0 and β + thalassemia patients. Genet Mol Res , 2011, 10(2): 632-639.
[3] Galano A, Medina ME, Tan DX, Reiter RJ. Melatonin and its metabolites as copper chelating agents and their role in inhibiting oxidative stress: a physicochemical analysis. J Pineal Res , 2015, 58(1): 107-116.
[4] McKay PJ, Murphy JA, Cameron S, Burnett AK, Campbell M, Tansey P, Franklin IM. Iron overload and liver dysfunction after allogeneic or autologous bone marrow transplantation. Bone Marrow Transplant , 1996, 17(1): 63-66.
[5] Ali S, Pimentel JD, Munoz J, Shah V, McKinnon R, Divine G, Janakiraman N. Iron overload in allogeneic hematopoietic stem cell transplant recipients. Arch Pathol Laborat Med , 2012, 136(5): 532-538.
[6] Trottier BJ, Burns LJ, DeFor TE, Cooley S, Majhail NS. Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content. Blood , 2013, 122(9): 1678-1684.
[7] Gordon LI, Brown SG, Tallman MS, Rademaker AW, Weitzman SA, Lazarus HM, Kelley CH, Mangan C, Rubin H, Fox RM, Creger RJ, Winter JN. Sequential changes in serum iron and ferritin in patients undergoing high-dose chemotherapy and radiation with autologous bone marrow transplantation: Possible implications for treatment related toxicity. Free Rad Biol Med , 1995, 18(3): 383-389.
[8] Meyer SC, O’Meara A, Buser AS, Tichelli A, Passweg JR, Stern M. Prognostic impact of posttransplantation iron overload after allogeneic stem cell transplantation. Biol Blood Marrow Tr , 2013, 19(3): 440-444.
[9] Busca A, Dellacasa C, Pecoraro C. Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation. Global J Hematol Blo , 2014, 1: 6-17.
[10] Sivgin S, Eser B. The management of iron overload in allogeneic hematopoietic stem cell transplant (alloHSCT) recipients: Where do we stand?. Ann Hematol , 2013, 92(5): 577-586.
[11] Muckenthaler MU. Red Cells, Iron, & Erythropoiesis: How mutant HFE causes hereditary hemochromatosis. Blood , 2014, 124(8): 1212.
[12] de Witte T. The role of iron in patients after bone marrow transplantation. Blood Rev , 2008, 22(Suppl. 2): S22-S28.
[13] Chua K, Fung E, Micewicz ED, Ganz T, Nemeth E, Ruchala P. Small cyclic agonists of iron regulatory hormone hepcidin. Bioorg Med Chem Lett , 2015, doi:10.1016/j.bmcl.2015.03.012.
[14] Sucak GT, Yaşar DG, Yegin ZA, Ergün MA, Özkurt ZN, Akı ŞZ, Güntekin S. The prognostic role of hemochromatosis H63D allele in allogeneic hematopoietic stem cell transplantation. Ann Hematol , 2012, 91(8): 1281-1287.
[15] Kaczorowska-Hac B, Szalewska M, Niedzwiecki M, Adamkiewicz-Drozynska E, Milosz E. Iron overload in two children after allogeneic hematopoietic SCT with concomitant HFE p.s65cgene mutation. J Blood Lymph , 2014, 4(1): 1000117.
[16] Finch C. Regulators of iron balance in humans. Blood , 1994, 84(6): 1697-1702.
[17] Liu QD, Davidoff O, Niss K, Haase VH. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J Clin Invest , 2012, 122(12): 4635.
[18] Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, Moroney JW, Reed CH, Luban NLC, Wang RH, Eling TE, Childs R, Ganz T, Leitman SF, Fucharoen S, Miller JL. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med , 2007, 13(9): 1096-1101.
[19] Tanno T, Porayette P, Sripichai O, Noh SJ, Byrnes C, Bhupatiraju A, Lee YT, Goodnough JB, Harandi O, Ganz T, Paulson RF, Miller JL. Identi

Metrics

Comments

www.chinagene.cn
备案号：京ICP备09063187号

Progress of iron-chelating therapy for iron overload in patients after bone marrow transplantation

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 0

Recommended Articles

Metrics

Comments